ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Influence of Aging on Outcomes of Sacubitril/Valsartan in Hypertensive Patients with Heart Failure: A Multicenter Retrospective Study [Anatol J Cardiol]
Anatol J Cardiol. 2024; 28(4): 194-200 | DOI: 10.14744/AnatolJCardiol.2023.3857

Influence of Aging on Outcomes of Sacubitril/Valsartan in Hypertensive Patients with Heart Failure: A Multicenter Retrospective Study

Chengchun Zuo1, Xiaoye Li1, Yingyun Guan2, Linlin Fan1, Jing Li1, Dan Tian1, Can Chen1, Xiaoyu Li1, Zhichun Gu3, Chi Zhang3, Xiaolan Bian2, Qianzhou Lv1
1Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China
2Department of Pharmacy, Ruijin Hospital School of Medicine, Shanghai Jiaotong University, Shanghai, China
3Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Background: The aim of this study was to investigate the influence of aging on the effectiveness and tolerance of sacubitril/valsartan (sac/val) among hypertensive patients complicated with heart failure in a real-world setting.

Methods: This multicenter, retrospective study included patients (≥18 years old) admitted with a diagnosis of hypertension and heart failure, starting sac/val therapy between January 2020 and December 2021 from 3 medical centers. Patients were grouped by the cutoff age of 65 years. Outcomes were collected 31-365 days after the initiation of sac/val and were compared in a matched cohort after 1: 1 propensity score matching (PSM).

Results: A total of 794 patients were finally analyzed. Blood pressure and cardiac functions improved significantly compared with values at baseline. There were 269 patients in each cohort (<65 years and ≥65 years) after PSM. After PSM, the incidence of hyperuricemia and hypotension in the elderly patients (≥65 years) was significantly higher than in those <65 years of age. Kaplan–Meier estimate suggested that the cumulative incidence of new or recurrent cardiovascular events increased significantly at the age of ≥65 years after the point of 3 months (log-rank P =.00087).

Conclusion: Sac/val benefited patients in both cohorts by improving blood pressure and cardiac function. Elderly patients (≥65 years) were susceptible to hypotension, low diastolic blood pressure, hyperuricemia, and underwent cardiac-related readmissions more frequently.

Keywords: Outcome, aging, heart failure, hypertension, sacubitril/valsartan

Chengchun Zuo, Xiaoye Li, Yingyun Guan, Linlin Fan, Jing Li, Dan Tian, Can Chen, Xiaoyu Li, Zhichun Gu, Chi Zhang, Xiaolan Bian, Qianzhou Lv. Influence of Aging on Outcomes of Sacubitril/Valsartan in Hypertensive Patients with Heart Failure: A Multicenter Retrospective Study. Anatol J Cardiol. 2024; 28(4): 194-200

Corresponding Author: Chengchun Zuo
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.